Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Intercontinental Ltd (Scrip Code 539938, BSE) has published the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2025, as approved by the Board on 30 May 2025. On a standalone basis, total income from operations for Q4 FY25 rose to ₹1,537.73 lakhs from ₹1,004.20 lakhs in Q4 FY24, a jump of about 53% year-on-year. Full-year FY25 standalone income stood at ₹6,763.75 lakhs versus ₹4,445.34 lakhs in FY24, up around 52%. Standalone net profit after tax for the year grew to ₹256.58 lakhs (FY24: ₹189.70 lakhs), with EPS of ₹2.57 versus ₹1.90. Consolidated FY25 income was ₹9,637.12 lakhs (FY24: ₹7,175.69 lakhs) and consolidated PAT was ₹505.73 lakhs (FY24: ₹394.71 lakhs), with consolidated EPS of ₹5.06 versus ₹3.95. Equity share capital remained unchanged at ₹1,000 lakhs and other equity rose to ₹2,866.15 lakhs.
The filing is a routine compliance newspaper publication, but the underlying numbers are clearly positive: strong double-digit growth in revenue, profit and EPS on both standalone and consolidated bases, which is supportive of the stock price and signals healthy operating momentum for shareholders.